文献速递心力衰竭与心肌病

心力衰竭住院患者中慢性肾脏病负担与结局

Burden of chronic kidney disease and outcomes following hospitalisation for heart failure.
PubMed 文献 · Heart · 2026-08-25

基于心衰住院患者随机对照试验的5年纵向队列分析,比较有/无慢性肾脏病诊断者的临床事件、医疗资源使用和直接成本。4441例中20.9%有CKD,CKD组调整死亡风险更高、生存期更短、再住院更多、成本近两倍,且基线无CKD者随访中至少83.4%被诊断CKD。

要点

  • 心衰住院患者中约五分之一存在CKD诊断,与死亡和再住院风险升高相关。
  • CKD组直接医疗成本近两倍,主要来自再住院。
  • 基线无CKD者随访中绝大多数后续被诊断CKD。

核心结论

  • 心衰住院时合并CKD常见,与更高死亡风险、更短生存期、更多再住院和近两倍直接医疗成本相关。
  • 基线无CKD的心衰住院患者中,绝大多数在随访期间被诊断CKD。

研究设计与样本

  • 为5年纵向队列分析,纳入心衰住院并参加Patient Centered Care Transitions in HF随机对照试验的患者。
  • 比较指数住院时有/无CKD诊断者的临床事件、医疗资源使用和直接医疗成本(加拿大元,经通胀调整),诊断和结局来自关联行政数据库。
  • 生存分析采用校正基线变量的Cox比例风险模型。

主要发现

  • 4441例心衰住院患者中929例(20.9%)在指数住院时已有CKD诊断。
  • CKD组调整死亡风险更高(调整HR 1.55,95%CI 1.42至1.69),平均生存期更短(2.2[1.8]年 vs 3.0[1.9]年)。
  • CKD组每人再住院次数更多(4.5[12.2]次 vs 2.5[6.6]次),住院天数更多(43.8[61.8]天 vs 22.7[42.3]天)。
  • CKD组接受更多门诊和诊断服务,校正基线特征后更少被配发ACE抑制剂或盐皮质激素受体拮抗剂。
  • CKD组年直接医疗成本近两倍(平均$C128 840[137 611] vs $C67 937[104 149] $C/年),主要来自再住院;基线无CKD者随访中至少83.4%被诊断CKD。

临床怎么用

  • 心衰住院患者应关注CKD诊断,因其与死亡、再住院和成本负担显著增加相关。
  • 对合并CKD的心衰患者,需注意ACE抑制剂和盐皮质激素受体拮抗剂的使用可能不足。
  • 基线无CKD的心衰住院患者应在随访中监测肾功能,因后续CKD诊断比例很高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The epidemiology and long-term healthcare utilisation associated with chronic kidney disease (CKD) among those with heart failure (HF) has not been mapped. METHODS: This is a 5-year longitudinal cohort analysis of patients hospitalised for HF and enrolled in the Patient Centered Care Transitions in HF randomised controlled trial. We compared clinical events, healthcare resource utilisation and direct healthcare costs (Canadian dollars, adjusted for inflation) between those with and without a CKD diagnosis at index hospitalisation. Diagnoses and outcomes were determined from linked, administrative databases. Survival was evaluated using Cox-proportional hazards models adjusted for baseline variables. RESULTS: Among 4441 patients hospitalised for HF, 929 (20.9%) had an established CKD diagnosis at index hospitalisation. Patients with CKD at index HF hospitalisation faced a higher adjusted risk of death (adjusted HR 1.55, 95% CI 1.42 to 1.69), poorer survival (mean [SD] 2.2 [1.8] vs 3.0 [1.9] years), more rehospitalisations (mean [SD] 4.5 [12.2] vs 2.5 [6.6] per patient) and more in-hospital days (mean [SD] 43.8 [61.8] vs 22.7 [42.3] per patient) than those without a diagnosis of CKD. Patients with a CKD diagnosis at index hospitalisation received more ambulatory and diagnostic services and were less likely to be dispensed an ACE inhibitor or mineralocorticoid receptor antagonist after adjusting for relevant baseline characteristics. Annual healthcare costs were nearly two times as high in patients with CKD at index hospitalisation than those without (mean [SD] $C128 840 [137 611] vs $C67 937 [104 149] $C/year), largely due to rehospitalisations. Among those without CKD at baseline, at least 83.4% received a CKD diagnosis during the follow-up period. CONCLUSIONS: CKD is common at index hospitalisation for HF and is associated with a higher risk of death, shorter lifespan, more rehospitalisations and nearly twice the direct healthcare costs than no CKD. A vast majority of patients without CKD at index hospitalisation for HF are diagnosed with it subsequently.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Averbuch, Greene, Biering-Sørensen, et al. Burden of chronic kidney disease and outcomes following hospitalisation for heart failure. Heart. 2026. PMID: 41775525. doi:10.1136/heartjnl-2025-327053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。